CDKN2A and meningioma: Sievers et al. analyzed CDKN2A/B homozygous deletion in 528 meningioma patients using DNA methylation and found this alteration in 26 cases (4.9%, 7 WHO grade 2 and 19 WHO grade 3) with significantly shorter TTP compared to tumors without this deletion [43].